Meeting
2022 ASCO Annual Meeting
Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort.
Authors
Marcela Carausu
Institut Curie, Saint-Cloud, France
Marcela Carausu , Matthieu Carton , Veronique C Dieras , Thierry Petit , Severine Guiu Lahaye , Corinne Veyret , Anthony Goncalves , Paule Augereau , Jean-Marc Ferrero , Christelle Levy , Mony Ung , Isabelle Desmoulins , Marc Debled , Thomas Bachelot , Jean-Christophe Eymard , Barbara Pistilli , Jean-Sebastien Frenel , Michaël Chevrot , Audrey Mailliez , Luc Cabel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1043)
DOI
10.1200/JCO.2022.40.16_suppl.1043
Abstract #
1043
Poster Bd #
421
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis.
First Author: Abby Statler
Poster
2019 ASCO Annual Meeting
Real-world treatment patterns and outcomes in ER+/PR+/HER2+ metastatic breast cancer (MBC) patients: A National Cancer Database analysis.
First Author: Abby Statler
Poster
2013 ASCO Annual Meeting
Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013.
First Author: Mark Danese
Poster
2024 ASCO Genitourinary Cancers Symposium
Patient characteristics, treatment patterns, and outcomes among early adopters of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617): A real-world United States (US) study.
First Author: Xiao X. Wei